MCID: ANG015
MIFTS: 57

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 76 55 6 44 15 73
Quincke's Edema 12 76
Angioneurotic Oedema 12
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
ICD10 33 T78.3
MeSH 44 D000799
NCIt 50 C112175
SNOMED-CT 68 41291007 82966003
UMLS 73 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as quincke's edema, is related to angioedema, hereditary, type i and acquired angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Omalizumab and Icatibant have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and endothelial.

Wikipedia : 76 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 229)
# Related Disease Score Top Affiliating Genes
1 angioedema, hereditary, type i 34.1 F12 SERPING1
2 acquired angioedema 34.0 C1S SERPING1
3 hereditary angioedema 33.5 ACE BDKRB2 C1S F12 KLKB1 KNG1
4 c1 inhibitor deficiency 32.7 BDKRB2 C1S KLKB1 KNG1 SERPING1
5 allergic urticaria 30.0 KNG1 SERPING1
6 urticaria 30.0 C1S CPN1 F12 HNMT LTC4S PTGS1
7 sinusitis 29.5 IL5 LTC4S
8 myocardial infarction 28.9 ACE KNG1 MME PTGS1 PTGS2
9 angioedema, hereditary, type iii 12.6
10 angioedema induced by ace inhibitors 12.6
11 episodic angioedema with eosinophilia 12.4
12 acquired angioedema type 2 12.1
13 vibratory urticaria 12.1
14 acquired angioedema type 1 12.0
15 complement component 4, partial deficiency of 11.5
16 carboxypeptidase n deficiency 11.0
17 netherton syndrome 11.0
18 loiasis 11.0
19 lupus erythematosus 10.3
20 systemic lupus erythematosus 10.2
21 lymphoma 10.2
22 hypereosinophilic syndrome 10.1
23 granulocytopenia 10.1
24 dermatitis 10.1
25 pancreatitis 10.1
26 peroneal neuropathy 10.1 CPN1 MME
27 drug-induced lupus erythematosus 10.1 F12 KLKB1
28 malignant essential hypertension 10.1 ACE KLKB1 KNG1
29 renal hypertension 10.1 ACE KLKB1 KNG1
30 contact dermatitis 10.1
31 vasculitis 10.1
32 chronic tic disorder 10.0 F12 IL5
33 arthritis 10.0
34 crohn's disease 10.0
35 acute pancreatitis 10.0
36 allergic contact dermatitis 10.0
37 ischemia 10.0
38 childhood type dermatomyositis 10.0
39 dermatomyositis 10.0
40 herpes gestationis 10.0
41 hypothyroidism 10.0
42 fibrillary glomerulonephritis 10.0
43 congestive heart failure 10.0 ACE KNG1 MME
44 aspirin resistance 10.0 PTGS1 PTGS2
45 helicobacter pylori infection 10.0
46 anxiety 10.0
47 physical urticaria 10.0
48 coproporphyria, hereditary 10.0
49 cyclic neutropenia 10.0
50 aging 10.0

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 242138-07-4
2
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
3
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 51-45-6, 75614-87-8 774
5
Loratadine Approved, Investigational Phase 4,Phase 2 79794-75-5 3957
6
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Enalapril Approved, Vet_approved Phase 4,Not Applicable 75847-73-3 5362032 40466924
9
Enalaprilat Approved Phase 4,Not Applicable 76420-72-9 6917719
10
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
12
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6
18
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
19
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
22
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
23
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
24
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
25
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
26
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
27 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
28 Vaccines Phase 4,Phase 2
29 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Kininogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Complement System Proteins Phase 4,Phase 3,Phase 2,Phase 1
43 Complement C1 Inactivator Proteins Phase 4,Phase 3,Phase 2,Phase 1
44 Complement C1s Phase 4,Phase 3,Phase 2,Phase 1
45 Complement C1 Inhibitor Protein Phase 4,Phase 3,Phase 2,Phase 1
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Complement Inactivating Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Bradykinin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
3 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
4 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
5 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
6 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
7 Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode. Completed NCT02554890 Phase 4 sacubitril/valsartan (LCZ696);Enalapril;sacubitril/valsartan (LCZ696) matching placebo;enalapril matching placebo
8 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
9 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4 ramipril;ramipril
10 Steroids in Fulminant Hepatitis A in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
11 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
12 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
13 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
14 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
15 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
16 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
17 A Study to Evaluate the Benefit of RUCONEST® in Subjects With CVID Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
18 Tranexamic Acid and Spontaneous Chronic Urticaria Not yet recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
19 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
20 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
21 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
22 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
23 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
24 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Completed NCT01919801 Phase 3 Icatibant;Placebo
25 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed NCT01723072 Phase 3 Placebo
26 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
27 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
28 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
29 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
30 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
31 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Completed NCT01386658 Phase 3 icatibant
32 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
33 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3 Icatibant;Placebo
34 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
35 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT02316353 Phase 3
36 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
37 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3 ecallantide
38 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
39 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
40 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3 Placebo (saline)
41 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
42 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
43 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
44 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
45 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
46 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3 Icatibant
47 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
48 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
49 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
50 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00289211 Phase 3 Placebo (saline)

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

41
Skin, Tongue, Endothelial, Brain, Liver, Heart, Bone

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 2044)
# Title Authors Year
1
Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema. ( 30534402 )
2019
2
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( 29951963 )
2018
3
Threshold-Stimulated Kallikrein Activity Distinguishes Bradykinin- From Histamine-Mediated Angioedema. ( 29957871 )
2018
4
Health-Related Quality-of-Life with Subcutaneous C1-inhibitor for Prevention of Attacks of Hereditary Angioedema. ( 29391286 )
2018
5
Efficacy of C1Inhibitor concentrate in hereditary angioedema with C1Inhibitor deficiency: analysis in the French Cohort. ( 29964227 )
2018
6
Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype. ( 29513108 )
2018
7
Case report presenting the diagnostic challenges in a patient with recurrent acquired angioedema, antiphospholipid antibodies and undetectable C2 levels. ( 29881401 )
2018
8
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease. ( 29423395 )
2018
9
Canadian Physician Survey on the Medical Management of Hereditary Angioedema. ( 29958877 )
2018
10
A transcriptomics study of hereditary angioedema attacks. ( 29729940 )
2018
11
Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema. ( 29866145 )
2018
12
Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies. ( 29279063 )
2018
13
Severe angioedema of laryngeal inlet in a woman receiving telmisartan therapy undergoing breast conservation surgery. ( 29910501 )
2018
14
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2A study. ( 29688579 )
2018
15
Enalapril-Induced Angioedema: Two Case Reports in a Rural Health Facility in Kenya. ( 29974027 )
2018
16
Hereditary Angioedema with Normal C1 Inhibitor: Four Types and Counting. ( 29410040 )
2018
17
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. ( 29316335 )
2018
18
Impaired Endothelial Function in Hereditary Angioedema During the Symptom-Free Period. ( 29867566 )
2018
19
Plasminogen gene mutation with normal C1Inhibitor-hereditary angioedema: Three additional French families. ( 29952006 )
2018
20
SERPING1 and F12 combined variants in a hereditary angioedema family<sup>,,a9^a9^a9^,a9^a9^a9^a9^</sup>. ( 29885370 )
2018
21
Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. ( 29439936 )
2018
22
Orolingual and abdominal angioedema post thrombolysis and thrombectomy. ( 29335305 )
2018
23
Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. ( 29909591 )
2018
24
Acquired Angioedema With Anti-C1-inhibitor Autoantibodies During Assisted Reproduction Techniques. ( 29461216 )
2018
25
Angioedema Associated With Nebulized Recombinant Human DNase in a Preterm Infant: Case Report. ( 29970979 )
2018
26
Tired and Swollen: A Mono Mimic for Angioedema. ( 29920345 )
2018
27
Malassezia infection associated with chronic spontaneous urticaria without angioedema: a report on five cases. ( 29945261 )
2018
28
Severe allergic contact dermatitis mimicking angioedema caused by propolis used as a traditional remedy. ( 29845630 )
2018
29
Atypical presentation of acquired angioedema. ( 29554170 )
2018
30
ACE Inhibitor-Induced Angioedema: a Review. ( 29884969 )
2018
31
Clinical Features of Hereditary Angioedema in Korean Patients: A Nationwide Multicenter Study. ( 29694969 )
2018
32
The Incidence and Frequency of Various Causes of Angioedema in Emergency Medicine. ( 29957967 )
2018
33
Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies-An application to the known association between angiotensin-converting enzyme inhibitors and angioedema. ( 29947045 )
2018
34
Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. ( 29393169 )
2018
35
Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. ( 29753808 )
2018
36
Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years. ( 29757016 )
2018
37
Amlodipine-induced angioedema: An unusual complication of a common medication. ( 29977650 )
2018
38
The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update. ( 29318628 )
2018
39
Hereditary Angioedema, Clinical Presentation and Socio-Economic Cost of 200 French Patients. ( 29936190 )
2018
40
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
41
Investigational drugs in phase I and phase II clinical trials for hereditary angioedema. ( 29226721 )
2018
42
Improving the Management of Hereditary Angioedema. ( 29791522 )
2018
43
The Diagnosis of Hereditary Angioedema: Family Caregivers' Experiences. ( 29862835 )
2018
44
Presymptomatic genetic diagnosis of two siblings with hereditary angioedema, presenting with unusual normal levels of serum C4. ( 29058329 )
2018
45
Unilateral orolingual angioedema after thrombolysis in a patient with cerebrovascular ischemia. ( 29947878 )
2018
46
Hereditary angioedema: The plasma contact system out of control. ( 29920929 )
2018
47
A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. ( 29548426 )
2018
48
Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. ( 29954477 )
2018
49
Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis. ( 29723342 )
2018
50
New Treatments for Hereditary Angioedema. ( 29357215 )
2018

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
3 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh38 Chromosome 11, 85734436: 85734436
4 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh37 Chromosome 11, 85445479: 85445479
5 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh37 Chromosome 11, 57382026: 57382026
6 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh38 Chromosome 11, 57614553: 57614553

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 DPP4 F12 KLKB1 KNG1 MME XPNPEP2
2
Show member pathways
11.97 ACE CPN1 DPP4 MME
3
Show member pathways
11.94 LTC4S PTGS1 PTGS2
4
Show member pathways
11.82 F12 KLKB1 KNG1 SERPING1
5
Show member pathways
11.7 LTC4S PTGS1 PTGS2
6 11.24 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
7 11.23 F12 KLKB1 SERPING1
8
Show member pathways
11.16 ACE BDKRB2 KNG1 MME
9 11.03 PTGS1 PTGS2
10 10.98 PTGS1 PTGS2
11
Show member pathways
10.96 PTGS1 PTGS2
12 10.87 ACE MME
13 10.86 PTGS1 PTGS2
14 10.76 PTGS1 PTGS2
15 10.71 LTC4S PTGS1 PTGS2
16 10.61 PTGS1 PTGS2

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ACE C1S CPN1 F12 IL5 KLKB1
2 extracellular region GO:0005576 9.65 ACE C1S CPN1 DPP4 F12 IL5
3 blood microparticle GO:0072562 9.43 C1S KNG1 SERPING1
4 extracellular exosome GO:0070062 9.32 ACE DPP4 F12 HNMT KLKB1 KNG1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.76 C1S CPN1 SERPING1
2 blood coagulation GO:0007596 9.76 F12 KLKB1 KNG1 SERPING1
3 inflammatory response GO:0006954 9.73 BDKRB2 IL5 KLKB1 KNG1 PTGS1 PTGS2
4 cellular oxidant detoxification GO:0098869 9.67 LTC4S PTGS1 PTGS2
5 regulation of blood pressure GO:0008217 9.65 ACE PTGS1 PTGS2
6 arachidonic acid secretion GO:0050482 9.62 ACE BDKRB2
7 regulation of vasoconstriction GO:0019229 9.61 ACE BDKRB2
8 long-chain fatty acid biosynthetic process GO:0042759 9.61 LTC4S PTGS2
9 prostaglandin metabolic process GO:0006693 9.6 PTGS1 PTGS2
10 vasodilation GO:0042311 9.59 BDKRB2 KNG1
11 prostaglandin biosynthetic process GO:0001516 9.58 PTGS1 PTGS2
12 zymogen activation GO:0031638 9.57 F12 KLKB1
13 peptide metabolic process GO:0006518 9.56 CPN1 MME
14 proteolysis GO:0006508 9.56 ACE C1S CPN1 DPP4 F12 KLKB1
15 amyloid-beta metabolic process GO:0050435 9.55 ACE MME
16 regulation of blood coagulation GO:0030193 9.54 F12 SERPING1
17 angiotensin maturation GO:0002003 9.52 ACE MME
18 cyclooxygenase pathway GO:0019371 9.51 PTGS1 PTGS2
19 fibrinolysis GO:0042730 9.5 F12 KLKB1 SERPING1
20 hemostasis GO:0007599 9.46 F12 KLKB1 KNG1 SERPING1
21 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 BDKRB2 PTGS2
22 positive regulation of fibrinolysis GO:0051919 9.4 F12 KLKB1
23 Factor XII activation GO:0002542 9.37 F12 KLKB1
24 blood coagulation, intrinsic pathway GO:0007597 8.92 F12 KLKB1 KNG1 SERPING1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.92 ACE C1S CPN1 DPP4 F12 KLKB1
2 serine-type endopeptidase activity GO:0004252 9.71 C1S DPP4 F12 KLKB1
3 heme binding GO:0020037 9.63 KLKB1 PTGS1 PTGS2
4 metallopeptidase activity GO:0008237 9.56 ACE CPN1 MME XPNPEP2
5 peroxidase activity GO:0004601 9.49 PTGS1 PTGS2
6 aminopeptidase activity GO:0004177 9.48 DPP4 XPNPEP2
7 serine-type peptidase activity GO:0008236 9.46 C1S DPP4 F12 KLKB1
8 dipeptidyl-peptidase activity GO:0008239 9.43 ACE DPP4
9 exopeptidase activity GO:0008238 9.37 ACE MME
10 peptidase activity GO:0008233 9.23 ACE C1S CPN1 DPP4 F12 KLKB1
11 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....